CAH Stock Analysis: Cardinal Health | NYSE

Pharmaceuticals, Medical Devices, Surgical Supplies, Radiopharmaceuticals

Total Rating 58

Safety 52

Buy Signal 0.49

Medical Distribution
Industry Rotation: +11.0

Market Cap: 55.0B
Avg Turnover: 398M

Risk 3d forecast

Volatility24.0%

VaR 5^th Pctl3.97%

VaR vs Median0.41%

Reward TTM

Sharpe Ratio1.45

Rel. Str. IBD78.7

Rel. Str. Peer Group57.9

Character TTM

Beta-0.003

Beta Downside-0.469

Hurst Exponent0.550

Drawdowns 3y

Max DD20.42%

CAGR/Max DD1.93

CAGR/Mean DD7.72

EPS (Earnings per Share)

EPS CAGR: 20.45%
EPS Trend: 97.5%

Last SUE: 4.00
Qual. Beats: 4

Revenue

Rev. CAGR: 6.20%
Rev. Trend: 90.7%

Last SUE: -4.00
Qual. Beats: -1

Warnings

Altman Z'' In Financial Distress Zone

Tailwinds

Confidence

Seasonality 11.7 years of data

Jan +2.2% 30

Feb +0.7% 19

Mar -0.1% 7

Apr -0.1% 7

May -1.3% 21

Jun +3.3% 9

Jul +2.1% 5

Aug -4.8% 31

Sep -1.9% 30

Oct -1.5% 11

Nov +5.8% 41

Dec -4.3% 30

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: CAH Cardinal Health

Cardinal Health, Inc. (NYSE: CAH) is a U.S.-headquartered healthcare services and products company that operates two reportable segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. Founded in 1979 and based in Dublin, Ohio, the company distributes branded, generic, and specialty pharmaceuticals along with over-the-counter health and consumer products to hospitals, health systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and home-care patients.

In addition to pharmaceutical distribution, Cardinal Health manufactures and distributes its own branded medical, surgical, and laboratory products (gloves, needles, wound care, surgical drapes, and procedure kits), offers pharmacy management services, operates community health center pharmacies, and provides supply chain solutions to healthcare providers. The company also produces and delivers radiopharmaceuticals, a specialized niche within nuclear medicine distribution.

As one of the large-cap players in the GICS Health Care Distributors sub-industry, Cardinal Health operates in a sector dominated by a few major U.S. pharmaceutical wholesalers that compete on scale, logistics efficiency, and service breadth rather than on product pricing. Its dual focus on pharmaceutical distribution and medical product manufacturing provides diversification across both drug and medical supply chains.

Headlines to Watch Out For

Opioid litigation settlements pressure earnings and free cash flow
Pharmaceutical segment margins compressed by generic drug pricing competition
Specialty Solutions revenue expands via oncology network acquisitions

Piotroski VR-10 (Strict) 6.0

Net Income: 1.71b TTM > 0 and > 6% of Revenue
FCF/TA: 0.08 > 0.02 and ΔFCF/TA 4.41 > 1.0
NWC/Revenue: -2.03% < 20% (prev -1.13%; Δ -0.89% < -1%)
CFO/TA 0.09 > 3% & CFO 5.17b > Net Income 1.71b
Net Debt (5.09b) to EBITDA (3.48b): 1.46 < 3
Current Ratio: 0.88 > 1.5 & < 3
Outstanding Shares: last quarter (237.0m) vs 12m ago -1.25% < -2%
Gross Margin: 3.84% > 18% (prev 3.67%; Δ 0.17% > 0.5%)
Asset Turnover: 460.5% > 50% (prev 419.0%; Δ 41.51% > 0%)
Interest Coverage Ratio: 7.25 > 6 (EBIT TTM 2.52b / Interest Expense TTM 348.0m)

Altman Z'' -0.22

A: -0.09 (Total Current Assets 38.8b - Total Current Liabilities 43.9b) / Total Assets 57.3b
B: 0.04 (Retained Earnings 2.01b / Total Assets 57.3b)
C: 0.05 (EBIT TTM 2.52b / Avg Total Assets 55.2b)
D: -0.05 (Book Value of Equity -2.88b / Total Liabilities 60.0b)
Altman-Z'' = -0.22 = B

Beneish M -3.06

DSRI: 0.91 (Receivables 13.8b/13.2b, Revenue 254b/223b)
GMI: 0.95 (GM 3.67% / 3.84%)
AQI: 0.97 (AQ_t 0.25 / AQ_t-1 0.26)
SGI: 1.14 (Revenue 254b / 223b)
TATA: -0.06 (NI 1.71b - CFO 5.17b) / TA 57.3b)
Beneish M = -3.06 (Cap -4..+1) = AA

What is the price of CAH shares?

As of October 13, 2026, the stock is trading at USD 238.08 with a total of 1,229,843 shares traded. Over the past week, the price has changed by +2.13%, over one month by +1.59%, over three months by +2.13% and over the past year by +55.75%.

Current recommended Stop Loss: 227.20 (which is 4.6% or 1.9 ATR below the current price).

Is CAH a buy, sell or hold?

Cardinal Health has received a consensus analysts rating of 4.47. Therefore, it is recommended to buy CAH.

StrongBuy: 11
Buy: 3
Hold: 3
Sell: 0
StrongSell: 0

What are the forecasts/targets for the CAH price?

Analysts Target Price	270.3	13.5%

Cardinal Health (CAH) - Fundamental Data Overview as of 13 October 2026

Market Cap USD = 55.0b (55.0b USD * 1.0 USD.USD)
P/E Trailing = 32.8589
P/E Forward = 17.6991
P/S = 0.2164
P/B = 16.0657
P/EG = 1.1136
Revenue TTM = 254b USD
EBIT TTM = 2.52b USD
EBITDA TTM = 3.48b USD
Long Term Debt = 7.00b USD (from longTermDebt, last quarter)
Short Term Debt = 2.08b USD (from shortTermDebt, last quarter)
Debt = 9.95b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.09b USD (calculated: Debt 9.95b - CCE 4.86b)
Enterprise Value = 60.1b USD (55.0b + Debt 9.95b - CCE 4.86b)
Interest Coverage Ratio = 7.25 (Ebit TTM 2.52b / Interest Expense TTM 348.0m)
EV/FCF = 13.28x (Enterprise Value 60.1b / FCF TTM 4.53b)
FCF Yield = 7.53% (FCF TTM 4.53b / Enterprise Value 60.1b)
FCF Margin = 1.78% (FCF TTM 4.53b / Revenue TTM 254b)
Net Margin = 0.67% (Net Income TTM 1.71b / Revenue TTM 254b)
Gross Margin = 3.84% ((Revenue TTM 254b - Cost of Revenue TTM 244b) / Revenue TTM)
Gross Margin QoQ = 4.30% (prev 4.10%)
Tobins Q-Ratio = 1.05 (Enterprise Value 60.1b / Total Assets 57.3b)
Interest Expense / Debt = 3.50% (Interest Expense 348.0m / Debt 9.95b)
Taxrate = 21.57% (469.0m / 2.17b)
NOPAT = 1.98b (EBIT 2.52b * (1 - 21.57%))
Current Ratio = 0.88 (Total Current Assets 38.8b / Total Current Liabilities 43.9b)
Debt / Equity = -3.45 (negative equity) (Debt 9.95b / totalStockholderEquity, last quarter -2.88b)
Debt / EBITDA = 1.46 (Net Debt 5.09b / EBITDA 3.48b)
Debt / FCF = 1.13 (Net Debt 5.09b / FCF TTM 4.53b)
Total Stockholder Equity = -2.87b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.10% (Net Income 1.71b / Total Assets 57.3b)
RoE = -59.73% (negative equity) (Net Income TTM 1.71b / Total Stockholder Equity -2.87b)
RoCE = 61.00% (EBIT 2.52b / Capital Employed (Equity -2.87b + L.T.Debt 7.00b))
RoIC = 18.62% (NOPAT 1.98b / Invested Capital 10.6b)
WACC = 5.48% (E(55.0b)/V(65.0b) * Re(5.97%) + D(9.95b)/V(65.0b) * Rd(3.50%) * (1-Tc(0.22)))
Discount Rate = 5.97% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.10 | Cagr: -1.46%
[DCF] Terminal Value 77.97% ; FCFF base≈3.46b ; Y1≈3.96b ; Y5≈5.83b
[DCF] Fair Price = 356.8 (EV 87.7b - Net Debt 5.09b = Equity 82.6b / Shares 231.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 97.53 | EPS CAGR: 20.45% | SUE: 4.0 | # QB: 4
Revenue Correlation: 90.73 | Revenue CAGR: 6.20% | SUE: -4.0 | # QB: -1
EPS current Quarter (2026-09-30): EPS=2.94 | Chg30d=+0.20% | Revisions=+10% | Analysts=14
EPS next Quarter (2026-12-31): EPS=3.12 | Chg30d=+0.24% | Revisions=+70% | Analysts=14
EPS current Year (2027-06-30): EPS=12.56 | Chg30d=-0.02% | Revisions=+84% | GrowthEPS=+14.7% | GrowthRev=+4.5%
EPS next Year (2028-06-30): EPS=14.06 | Chg30d=-0.14% | Revisions=+69% | GrowthEPS=+11.9% | GrowthRev=+6.0%
[Analyst] Revisions Ratio: +76% (up=39, down=4)